Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(5):759–765. doi: 10.1038/bjc.1996.433

Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma.

W Müller 1, A Schneiders 1, S Meier 1, G Hommel 1, H E Gabbert 1
PMCID: PMC2074700  PMID: 8795579

Abstract

The prognostic significance of tumour cell proliferation was investigated in a series of 418 gastric carcinomas using the monoclonal antibody MIB-1. Owing to strong intratumoural heterogeneity of MIB-1 expression three different proliferation indices (PIs) were determined in all carcinomas: (1) PImax in areas of maximal tumour cell proliferation, (2) PIrand in areas randomly distributed over the whole tumour. (3) PIfront in areas exclusively located at the tumour invasion front. There was a strong intertumoral heterogeneity with PImax ranging from 4.9% to 92.2%, PIrand ranging from 3.4% to 81.4% and PIfront ranging from 4.2% to 87.1%. The mean values were 51.3% +/- 19.7 for PImax, 34.2% +/- 18.3 for PIrand and 37.2% +/- 19.5 for PIfront. Whereas no statistically significant correlation could be found between proliferative activity and the clinicopathological parameters depth of invasion, lymph node involvement or grade of tumour differentiation, there was a positive correlation between a high proliferation index at the tumour invasion front (PIfront) and the presence of blood or lymphatic vessel invasion. No significant correlation could be demonstrated between the different proliferation indices and survival, even when different subgroups of patients were analysed separately. The present results suggest that the immunohistochemical evaluation of the proliferation activity has no predictive value for the prognosis of gastric cancer patients or the identification of subgroups of patients who may be at higher risk.

Full text

PDF
759

Images in this article

760Figure 1
on p.760

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaltomaa S., Lipponen P., Syrjänen K. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res. 1993 Mar-Apr;13(2):533–538. [PubMed] [Google Scholar]
  2. Bravo R. Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp Cell Res. 1986 Apr;163(2):287–293. doi: 10.1016/0014-4827(86)90059-5. [DOI] [PubMed] [Google Scholar]
  3. Brown D. C., Gatter K. C. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990 Dec;17(6):489–503. doi: 10.1111/j.1365-2559.1990.tb00788.x. [DOI] [PubMed] [Google Scholar]
  4. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  5. Cummings M. C., Furnival C. M., Parsons P. G., Townsend E. PCNA immunostaining in breast cancer. Aust N Z J Surg. 1993 Aug;63(8):630–636. doi: 10.1111/j.1445-2197.1993.tb00471.x. [DOI] [PubMed] [Google Scholar]
  6. Fujii M., Motoi M., Saeki H., Aoe K., Moriwaki S. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer. Acta Med Okayama. 1993 Apr;47(2):103–108. doi: 10.18926/AMO/31567. [DOI] [PubMed] [Google Scholar]
  7. Gabbert H. E., Meier S., Gerharz C. D., Hommel G. Incidence and prognostic significance of vascular invasion in 529 gastric-cancer patients. Int J Cancer. 1991 Sep 9;49(2):203–207. doi: 10.1002/ijc.2910490210. [DOI] [PubMed] [Google Scholar]
  8. Gabbert H. Mechanisms of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev. 1985;4(4):293–309. doi: 10.1007/BF00048094. [DOI] [PubMed] [Google Scholar]
  9. Gabbert H., Wagner R., Höhn P. The relation between tumor cell proliferation and vascularization in differentiated and undifferentiated colon carcinomas in the rat. Virchows Arch B Cell Pathol Incl Mol Pathol. 1982;41(1-2):119–131. doi: 10.1007/BF02890276. [DOI] [PubMed] [Google Scholar]
  10. Gasparini G., Bevilacqua P., Pozza F., Meli S., Boracchi P., Marubini E., Sainsbury J. R. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer. 1992 Nov;66(5):970–976. doi: 10.1038/bjc.1992.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  12. Haerslev T., Jacobsen G. K. Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors. Virchows Arch. 1994;424(1):39–46. doi: 10.1007/BF00197391. [DOI] [PubMed] [Google Scholar]
  13. Harper M. E., Glynne-Jones E., Goddard L., Wilson D. W., Matenhelia S. S., Conn I. G., Peeling W. B., Griffiths K. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate. 1992;20(3):243–253. doi: 10.1002/pros.2990200309. [DOI] [PubMed] [Google Scholar]
  14. Hemming A. W., Davis N. L., Kluftinger A., Robinson B., Quenville N. F., Liseman B., LeRiche J. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol. 1992 Nov;51(3):147–152. doi: 10.1002/jso.2930510304. [DOI] [PubMed] [Google Scholar]
  15. Henriksen R., Strang P., Backstrom T., Wilander E., Tribukait B., Oberg K. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res. 1994 Mar-Apr;14(2B):603–608. [PubMed] [Google Scholar]
  16. Isola J., Kallioniemi O. P., Korte J. M., Wahlström T., Aine R., Helle M., Helin H. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol. 1990 Dec;162(4):295–301. doi: 10.1002/path.1711620404. [DOI] [PubMed] [Google Scholar]
  17. Jain S., Filipe M. I., Hall P. A., Waseem N., Lane D. P., Levison D. A. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol. 1991 Aug;44(8):655–659. doi: 10.1136/jcp.44.8.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jordan P. A., Kerns B. J., Pence J. C., Kohler M. F., Bast R. C., Jr, Kinney R. B., Berchuck A. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol. 1993 Jun;99(6):736–740. doi: 10.1093/ajcp/99.6.736. [DOI] [PubMed] [Google Scholar]
  19. Kakeji Y., Korenaga D., Tsujitani S., Haraguchi M., Maehara Y., Sugimachi K. Predictive value of Ki-67 and argyrophilic nucleolar organizer region staining for lymph node metastasis in gastric cancer. Cancer Res. 1991 Jul 1;51(13):3503–3506. [PubMed] [Google Scholar]
  20. Kerns B. J., Jordan P. A., Faerman L. L., Berchuck A., Bast R. C., Jr, Layfield L. J. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol. 1994 Feb;101(2):192–197. doi: 10.1093/ajcp/101.2.192. [DOI] [PubMed] [Google Scholar]
  21. Kubota Y., Petras R. E., Easley K. A., Bauer T. W., Tubbs R. R., Fazio V. W. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer. 1992 Dec 1;70(11):2602–2609. doi: 10.1002/1097-0142(19921201)70:11<2602::aid-cncr2820701106>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  22. LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965;64:31–49. doi: 10.1111/apm.1965.64.1.31. [DOI] [PubMed] [Google Scholar]
  23. Lipponen P. K., Eskelinen M. J. Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer. 1992 Jul;66(1):171–176. doi: 10.1038/bjc.1992.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Macdonald-Bravo H., Bravo R. Induction of the nuclear protein cyclin in serum-stimulated quiescent 3T3 cells is independent of DNA synthesis. Exp Cell Res. 1985 Feb;156(2):455–461. doi: 10.1016/0014-4827(85)90552-x. [DOI] [PubMed] [Google Scholar]
  25. Maeda K., Chung Y. S., Takatsuka S., Ogawa Y., Onoda N., Sawada T., Kato Y., Nitta A., Arimoto Y., Kondo Y. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer. 1995 Aug;72(2):319–323. doi: 10.1038/bjc.1995.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mayer A., Takimoto M., Fritz E., Schellander G., Kofler K., Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993 Apr 15;71(8):2454–2460. doi: 10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  27. Mori M., Kakeji Y., Adachi Y., Moriguchi S., Maehara Y., Sugimachi K., Jessup J. M., Chen L. B., Steele G. D., Jr The prognostic significance of proliferating cell nuclear antigen in clinical gastric cancer. Surgery. 1993 Jun;113(6):683–690. [PubMed] [Google Scholar]
  28. Mulder A. H., Van Hootegem J. C., Sylvester R., ten Kate F. J., Kurth K. H., Ooms E. C., Van der Kwast T. H. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol. 1992 Jan;166(1):37–43. doi: 10.1002/path.1711660107. [DOI] [PubMed] [Google Scholar]
  29. Porschen R., Kriegel A., Langen C., Classen S., Hilse M., Lohe B., Hengels K. J., Borchard F. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. Int J Cancer. 1991 Mar 12;47(5):686–691. doi: 10.1002/ijc.2910470510. [DOI] [PubMed] [Google Scholar]
  30. Quinn C. M., Wright N. A. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol. 1990 Feb;160(2):93–102. doi: 10.1002/path.1711600202. [DOI] [PubMed] [Google Scholar]
  31. Railo M., Nordling S., von Boguslawsky K., Leivonen M., Kyllönen L., von Smitten K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer. 1993 Sep;68(3):579–583. doi: 10.1038/bjc.1993.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Siitonen S. M., Kallioniemi O. P., Isola J. J. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. Am J Pathol. 1993 Apr;142(4):1081–1089. [PMC free article] [PubMed] [Google Scholar]
  33. Skopelitou A., Korkolopoulou P., Papanicolaou A., Christodoulou P., Thomas-Tsagli E., Pavlakis K. Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters. Eur Urol. 1992;22(3):235–240. doi: 10.1159/000474762. [DOI] [PubMed] [Google Scholar]
  34. Thomas H., Nasim M. M., Sarraf C. E., Alison M. R., Love S., Lambert H. E., Price P. Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer? Br J Cancer. 1995 Feb;71(2):357–362. doi: 10.1038/bjc.1995.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Thomas M., Noguchi M., Kitagawa H., Kinoshita K., Miyazaki I. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol. 1993 Jun;46(6):525–528. doi: 10.1136/jcp.46.6.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tubiana M., Pejovic M. H., Koscielny S., Chavaudra N., Malaise E. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer. 1989 Jul 15;44(1):17–22. doi: 10.1002/ijc.2910440104. [DOI] [PubMed] [Google Scholar]
  37. Yonemura Y., Kimura H., Fushida S., Tugawa K., Nakai Y., Kaji M., Fonseca L., Yamaguchi A., Miyazaki I. Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy. Cancer. 1993 Apr 15;71(8):2448–2453. doi: 10.1002/1097-0142(19930415)71:8<2448::aid-cncr2820710804>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  38. Yonemura Y., Ohoyama S., Kimura H., Kamata T., Matsumoto H., Yamaguchi A., Kosaka T., Miwa K., Miyazaki I. The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. Cancer. 1991 May 15;67(10):2523–2528. doi: 10.1002/1097-0142(19910515)67:10<2523::aid-cncr2820671023>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  39. Yonemura Y., Ohoyama S., Kimura H., Kamata T., Yamaguchi A., Miyazaki I. Assessment of tumor cell kinetics by monoclonal antibody Ki-67. Eur Surg Res. 1990;22(6):365–370. doi: 10.1159/000129123. [DOI] [PubMed] [Google Scholar]
  40. Yonemura Y., Ooyama S., Sugiyama K., Ninomiya I., Kamata T., Yamaguchi A., Matsumoto H., Miyazaki I. Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67. Cancer. 1990 Mar 1;65(5):1130–1134. doi: 10.1002/1097-0142(19900301)65:5<1130::aid-cncr2820650516>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  41. al-Sheneber I. F., Shibata H. R., Sampalis J., Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer. 1993 Mar 15;71(6):1954–1959. doi: 10.1002/1097-0142(19930315)71:6<1954::aid-cncr2820710605>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES